Table 4. Strength of Evidence.
Author | Hb | Transfusion rate | Significant AE | QOL | Infections | LOS | Mortality |
---|---|---|---|---|---|---|---|
Cladellas et al, 2012 [32] | X | X | X | X | X | X | |
Urena et al, 2017 [34] | X | X | X | X | X | X | |
Johansson et al, 2015 [36] | X | X | X | X | X | ||
Padmanabhan et al, 2018 [35] | X | X | X | X | X | X | X |
Garrido-Martin et al, 2012 [33] | X | X | X | X | |||
Spahn et al, 2019 [37] | X | X | X | X | X | X | |
Summary of Level of Evidencea | (6) 1b | (6) 1b | (6) 1b | (1) 2b | (6) 1b | (4) 1b | (5) 1b |
Quality of Body of Evidenceb | Moderate | Moderate | Moderate | Low | Moderate | Moderate | Moderate |
aOxford Centre for Evidence-based Medicine’s “Levels of Evidence.” https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/; bCincinnati Children’s Hospital Medical Center Evidence Collaboration’s, file:///Users/kellytankard/Downloads/Guideline%20Development%20Manual%20(1).pdf. AE: adverse event; Hb: hemoglobin; QOL: quality of life; LOS: length of stay.